Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Laurence T, Rimsky"'
Autor:
Johan Vingerhoets, Sandra De Meyer, Kim Thys, Veerle Van Eygen, Carl Van Hove, Gaston Picchio, Laurence T. Rimsky, Jeroen Aerssens
Publikováno v:
Journal of Medical Virology. 88:798-806
Minority variants (1.0-25.0%) were evaluated by deep sequencing (DS) at baseline and virological failure (VF) in a selection of antiretroviral treatment-naive, HIV-1-infected patients from the rilpivirine ECHO/THRIVE phase III studies. Linkage betwee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4e24a869e7c3c92553a4c4504f591e4
https://doi.org/10.1002/jmv.24395
https://doi.org/10.1002/jmv.24395
Autor:
Georg Behrens, Jennifer Demorin, Simon Vanveggel, Susan K. Chuck, Calvin J. Cohen, Bart J. A. Rijnders, Marita Stevens, Richard Elion, David Thorpe, Laurence T. Rimsky, Chloe Orkin, Mark T. Nelson, Anthony Mills, Matthew Bosse, Lijie Zhong, Kirsten L. White
Publikováno v:
AIDS Patient Care and STDs, 28(4), 168-175. Mary Ann Liebert Inc.
The once daily, single-tablet regimen (STR) combining rilpivirine (RPV), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) provides a simplified treatment option for antiretroviral therapy (ART)-naive patients with baseline HIV-1 RNA (BLVL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::911adb8c4a3803b4d4deb62109946f12
https://hdl.handle.net/1765/57280
https://hdl.handle.net/1765/57280
Autor:
Echo, Simon Vanveggel, Chloe Orkin, J.-M. Molina, Marita Stevens, Laurence T. Rimsky, Nathan Clumeck, Thrive study groups
Publikováno v:
HIV Medicine. 15:57-62
Objectives These 96-week, ECHO/THRIVE pooled analyses evaluated data for antiretroviral treatment-naive, HIV-1-infected adults with viral load (VL) ≤ 100 000 HIV-1 RNA copies/mL receiving rilpivirine or efavirenz. Methods ECHO and THRIVE were phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eac59ef7cfc4d92f0ab077d80734955d
https://doi.org/10.1111/hiv.12071
https://doi.org/10.1111/hiv.12071
Autor:
Karla Redant, Simon Vanveggel, Laurence T. Rimsky, Marita Stevens, Jean-Michel Molina, Nathan Clumeck
Publikováno v:
AIDS. 27:889-897
OBJECTIVES To compare efficacy, resistance development, and safety between rilpivirine and efavirenz in treatment-naive, HIV-1-infected adults with baseline viral load 100,000 copies/ml or less in the pooled 48-week dataset of the ECHO (Efficacy Comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::589854731330da21efaff5ee3021352b
https://doi.org/10.1097/qad.0b013e32835e1554
https://doi.org/10.1097/qad.0b013e32835e1554
Autor:
Katia Boven, Simon Vanveggel, Gaston Picchio, Steven Nijs, Johan Vingerhoets, Laurence T. Rimsky, Veerle Van Eygen
Publikováno v:
Antiviral Therapy. 18:253-256
Background Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbe797e5636562001dd5681f0e93bd61
https://doi.org/10.3851/imp2358
https://doi.org/10.3851/imp2358
Autor:
Aimee, Wilkin, Anton L, Pozniak, Javier, Morales-Ramirez, Sergio H, Lupo, Mario, Santoscoy, Beatriz, Grinsztejn, Kiat, Ruxrungtham, Laurence T, Rimsky, Simon, Vanveggel, Katia, Boven, Melanie, Thompson
Publikováno v:
AIDS Research and Human Retroviruses. 28:437-446
TMC278-C204 (NCT00110305), a 96-week trial of the nonnucleoside reverse transcription inhibitor (NNRTI) rilpivirine (RPV, TMC278) in 368 HIV-1-infected, treatment-naive patients, was extended to investigate long-term safety and efficacy. Week 192 ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5f975ea759a796a04072eff99c8d348
https://doi.org/10.1089/aid.2011.0050
https://doi.org/10.1089/aid.2011.0050
Autor:
Kerim Babaoglu, Eric B. Lansdon, Evguenia S. Svarovskaia, Laurence T. Rimsky, Veerle Van Eygen, Gaston Picchio, Michael D. Miller, Kirsten L. White, Rima Kulkarni
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 59:47-54
Background The registrational phase III clinical trials of the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) rilpivirine (RPV) in combination with two nucleoside/nucleotide RT inhibitors (NRTIs) found a unique genotypic resistance patter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1678a33b8dd0392aa46063257165be2
https://doi.org/10.1097/qai.0b013e31823aca74
https://doi.org/10.1097/qai.0b013e31823aca74
Autor:
Khuanchai Supparatpinyo, Herta Crauwels, Jean-Michel Molina, Simon Vanveggel, Anthony Mills, Laurence T. Rimsky, Adriano Lazzarin, Michael S. Saag, Sharon Walmsley, Pedro Cahn, Katia Boven, Beatriz Grinsztejn
Publikováno v:
The Lancet. 378:238-246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non-nucleoside reverse transcriptase inhibitor, has shown sim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc13bd78fe7a3bac16d4e8d194eaf9c8
https://doi.org/10.1016/s0140-6736(11)60936-7
https://doi.org/10.1016/s0140-6736(11)60936-7
Autor:
Steven Nijs, Johan Vingerhoets, Goedele De Smedt, Sandra De Meyer, Inge Dierynck, Hilde Azijn, Laurence T. Rimsky, Gaston Picchio, Marie-Pierre de Béthune, Lotke Tambuyzer
Publikováno v:
AIDS Research and Human Retroviruses. 26:621-624
Etravirine (ETR) has previously shown potent in vitro activity against different primary HIV-1 isolates and demonstrated durable efficacy in treatment-experienced, HIV-1-infected patients in the Phase III DUET studies. The antiviral activity and effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b236c0c03d66dbab097936be381015a
https://doi.org/10.1089/aid.2009.0239
https://doi.org/10.1089/aid.2009.0239
Autor:
Anton L, Pozniak, Javier, Morales-Ramirez, Elly, Katabira, Dewald, Steyn, Sergio H, Lupo, Mario, Santoscoy, Beatriz, Grinsztejn, Kiat, Ruxrungtham, Laurence T, Rimsky, Simon, Vanveggel, Katia, Boven, Aimee, Wilkin
Publikováno v:
AIDS. 24:55-65
OBJECTIVE TMC278 is a next-generation nonnucleoside reverse transcriptase inhibitor highly active against wild-type and nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in vitro. The week 96 analysis of TMC278-C204, a large dose-ranging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2989a64522eb89ac292a997dcefbd39
https://doi.org/10.1097/qad.0b013e32833032ed
https://doi.org/10.1097/qad.0b013e32833032ed